Accès ouvert
2026
preprint
OpenAlex
Ye Zhou, Yajing Wu, Na Zhang, Shuo Wang et autres
Objective: Preclinical studies suggest that irradiation combined with anti-PD-1 antibody (iRT) exacerbates cardiac injury in mice, partly through CD8⁺ T-cell-mediated mechanisms. We investigated radiation-induced PD-L1 expression in cardiomyocytes and explored its potential role in iRT-associated cardiac injury. Methods: AC16 cells were exposed …
cn
(code pays fourni par la source)
Accès ouvert
2026
preprint
OpenAlex
Guoqiang LIU, Yonggang YU, Fei Liu, Zexian Fu et autres
cn
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Huanhuan Zhang, Hongwei Zhang, Xueshuai Ye, Jing Yang et autres
BACKGROUND: Moutan Cortex (MC), the dried root bark of Paeonia × suffruticosa Andrews, is used as both a medicinal and edible product and possesses hepatoprotective and anti-inflammatory properties. It is rich in bioactive polysaccharide components. However, the role of a polysaccharide-rich preparation …
cn
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
T. Zhang, Yue Chong Wang, Jiuna Zhang, Xueshuai Ye et autres
Gastric cancer (GC) remains among the cancers with extremely high morbidity and mortality rates worldwide, and chemotherapy resistance limits its therapeutic efficacy. Therapy‑induced senescence (TIS) is vital for inducing chemotherapy resistance and promoting tumor progression, highlighting the need to explore its regulatory …
cn
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Yang Li, Xueqian Zhang, Guiyu Liu, Tianci Tang et autres
BACKGROUND: Umbilical cord mesenchymal stem cells (UC-MSCs) transplantation has emerged as a promising therapeutic approach of liver fibrosis. However, UC-MSCs have limited anti-fibrotic ability for various reasons. In this study, we aimed to investigate whether the overexpression of CXCL9 in UC-MSCs (CXCL9-UC-MSC) …
cn
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Xueshuai Ye, Min Ge, M. Tan, Yongqiang Wu et autres
CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has achieved marvelous results in the treatment of patients with relapsed and/or refractory B-cell lymphomas, B-cell acute lymphoblastic leukemia, and multiple myeloma. As a new treatment method that has changed the existing treatment paradigm, there …
cn
(code pays fourni par la source)
Accès ouvert
2024
preprint
OpenAlex
Tianci Tang, Xueshuai Ye, Yang Li, Guan Liu et autres
Abstract Aging and cancer are interconnected, with studies suggesting that the aging-related secretory phenotype can induce transformation between epithelial and stromal cells, as well as tumor angiogenesis. This connection suggests the feasibility of a treatment strategy that simultaneously targets tumor cells and …
cn
(code pays fourni par la source)
Accès ouvert
2024
preprint
OpenAlex
Yang Li, Xueqian Zhang, Guiyu Liu, Junye Wen et autres
cn
(code pays fourni par la source)
2023
article
OpenAlex
Xueshuai Ye, Yongqiang Wu, Hai-Qiang Zhang, Long Shi et autres
cn
(code pays fourni par la source)
Accès ouvert
2022
preprint
OpenAlex
Xueshuai Ye, Yongqiang Wu, Ziqi Cai, Qichen Yuan et autres
Abstract Manufacturing CAR (chimeric antigen receptor)-T cell with viral vector is expensive and time-consuming. Besides, during viral transduction, the genes encoding CARs are randomly integrated into the genome, which could cause oncogenesis or produce devastating CAR-tumor cells. Here, using virus-free and non-transgenic …
cn, us
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Hezhi Wang, Xiaoxiao Wang, Xueshuai Ye, Yi Ju et autres
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and the adoptive immunotherapy of which is worth studying. CD133, a kind of cancer stem cell (CSC) antigen, together with glypican-3 (GPC3) has been proved to be highly expressed in …
cn
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Hai-Qiang Zhang, Xueshuai Ye, Junye Wen, Ziqi Cai et autres
HER-2 targeted therapies, such as monoclonal antibodies (mAbs) and CAR-T cell therapy have been applied in the treatment of various of cancers. However, the anti-HER2 CAR-T cell therapy are limited by its expensive production procedure and fatal side effects such as cytokine …
cn
(code pays fourni par la source)